DIMP Stock Overview Engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Sartorius Stedim Biotech S.A. Competitors Price History & Performance
Summary of share price highs, lows and changes for Sartorius Stedim Biotech Historical stock prices Current Share Price €227.70 52 Week High €274.10 52 Week Low €143.60 Beta 0.66 1 Month Change 22.75% 3 Month Change 21.13% 1 Year Change 2.52% 3 Year Change -42.38% 5 Year Change 32.46% Change since IPO 1,870.01%
Recent News & Updates
Sartorius Stedim Biotech S.A., Annual General Meeting, Mar 25, 2025 Jan 30 Sartorius Stedim Biotech S.A. to Report First Half, 2025 Results on Jul 22, 2025
Sartorius Stedim Biotech S.A. to Report Q1, 2025 Results on Apr 17, 2025 Jan 18
Sartorius Stedim Biotech S.A. to Report Fiscal Year 2024 Results on Jan 28, 2025 Nov 16
Insufficient new directors May 09
Investor sentiment deteriorates as stock falls 27% Apr 25 See more updates
Sartorius Stedim Biotech S.A., Annual General Meeting, Mar 25, 2025 Jan 30 Sartorius Stedim Biotech S.A. to Report First Half, 2025 Results on Jul 22, 2025
Sartorius Stedim Biotech S.A. to Report Q1, 2025 Results on Apr 17, 2025 Jan 18
Sartorius Stedim Biotech S.A. to Report Fiscal Year 2024 Results on Jan 28, 2025 Nov 16
Insufficient new directors May 09
Investor sentiment deteriorates as stock falls 27% Apr 25
Insufficient new directors Apr 24
Upcoming dividend of €0.69 per share Mar 26
New minor risk - Profit margin trend Feb 18
Dividend of €0.69 announced Feb 12
Insufficient new directors Feb 09
Sartorius Stedim Biotech S.A. has filed a Follow-on Equity Offering in the amount of €1.2 billion. Feb 08 Sartorius Stedim Biotech S.A. has completed a Follow-on Equity Offering in the amount of €1.2 billion.
Insufficient new directors Jan 12 Sartorius Stedim Biotech S.A. to Report Nine Months, 2024 Results on Oct 17, 2024
Investor sentiment improves as stock rises 16% Dec 18
Insufficient new directors Dec 05
Third quarter 2023 earnings released: EPS: €0.28 (vs €2.22 in 3Q 2022) Oct 20
Investor sentiment deteriorates as stock falls 16% Oct 13
Less than half of directors are independent Sep 14
Second quarter 2023 earnings released: EPS: €1.44 (vs €2.33 in 2Q 2022) Jul 21
Less than half of directors are independent Jul 13
Investor sentiment deteriorates as stock falls 15% Jun 24
Less than half of directors are independent Jun 09
Less than half of directors are independent May 13
Less than half of directors are independent Apr 22
Less than half of directors are independent Mar 31
Full year 2022 earnings released: EPS: €9.51 (vs €4.50 in FY 2021) Feb 18 Sartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2023
Less than half of directors are independent Jan 05
Sartorius Stedim Biotech S.A. to Report Fiscal Year 2022 Results on Jan 26, 2023 Dec 22
Sartorius Stedim Biotech S.A., Annual General Meeting, Mar 27, 2023 Dec 08
Less than half of directors are independent Nov 25
Third quarter 2022 earnings released: EPS: €2.22 (vs €1.60 in 3Q 2021) Oct 21
Sartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2022 Oct 19
Sartorius Stedim Biotech S.A. (ENXTPA:DIM) entered into a definitive agreement to acquire Albumedix Ltd. from private investors for approximately £420 million. Aug 10
Second quarter 2022 earnings released: EPS: €2.33 (vs €1.61 in 2Q 2021) Jul 23
Less than half of directors are independent Apr 29
First quarter 2022 earnings released: EPS: €2.93 (vs €1.24 in 1Q 2021) Apr 22
Sartorius Stedim Biotech S.A. Confirms Earnings Guidance for the Year 2022 Apr 21
Sartorius Stedim Biotech S.A. Approves Dividend for the Fiscal Year 2021 Mar 30
Upcoming dividend of €1.26 per share Mar 21
Less than half of directors are independent Mar 01
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 20
Sartorius Stedim Biotech S.A. Updates Earnings Guidance for the Year 2022 Feb 18
Sartorius Stedim Biotech S.A. Recommends Dividend Feb 10
Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of chromatography equipment division from Novasep Holding SAS. Feb 08
Sartorius Stedim Biotech Provides Earnings Guidance for the Full Year 2022 Jan 27
Third quarter 2021 earnings released: EPS €1.60 (vs €1.10 in 3Q 2020) Oct 21
Second quarter 2021 earnings released: EPS €1.56 (vs €0.73 in 2Q 2020) Jul 22
Sartorius Stedim Biotech S.A. Raises Forecast for the Full Year 2021 Jul 07
First quarter 2021 earnings released: EPS €1.24 (vs €0.81 in 1Q 2020) Apr 25
Sartorius Stedim Biotech Raises Consolidated Sales Guidance for 2021 Apr 24
Sartorius Stedim Biotech Increases Earnings Guidance for 2021 Mar 19
Full year 2020 earnings released: EPS €3.88 (vs €2.54 in FY 2019) Feb 21
Revenue misses expectations Feb 21
New 90-day high: €362 Feb 03 Sartorius Stedim Biotech S.A. to Report Nine Months, 2021 Results on Oct 20, 2021
Sartorius Stedim Biotech S.A. (ENXTPA:DIM) signed an agreement to acquire chromatography equipment division from Novasep Holding SAS. Jan 08
Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of BIA Separations d.o.o. Nov 03 Sartorius Stedim Biotech S.A. to Report Q1, 2021 Results on Apr 21, 2021
Sartorius Stedim Biotech S.A. (ENXTPA:DIM) entered into a definitive agreement to acquire BIA Separations d.o.o. for ?€360 million. Oct 03
Sartorius Aktiengesellschaft (XTRA:SRT) and Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of certain businesses from Danaher Corporation (NYSE:DHR). Jul 30 Shareholder Returns DIMP GB Life Sciences GB Market 7D 9.3% -0.9% 1.0% 1Y 2.5% -10.5% 10.4%
See full shareholder returns
Return vs Market: DIMP underperformed the UK Market which returned 9% over the past year.
Price Volatility Is DIMP's price volatile compared to industry and market? DIMP volatility DIMP Average Weekly Movement 7.8% Life Sciences Industry Average Movement 8.3% Market Average Movement 4.8% 10% most volatile stocks in GB Market 11.0% 10% least volatile stocks in GB Market 2.7%
Stable Share Price: DIMP's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine DIMP's volatility change over the past year.
About the Company Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products.
Show more Sartorius Stedim Biotech S.A. Fundamentals Summary How do Sartorius Stedim Biotech's earnings and revenue compare to its market cap? DIMP fundamental statistics Market cap €21.89b Earnings (TTM ) €160.60m Revenue (TTM ) €2.74b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) DIMP income statement (TTM ) Revenue €2.74b Cost of Revenue €1.55b Gross Profit €1.19b Other Expenses €1.02b Earnings €160.60m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 17, 2025
Earnings per share (EPS) 1.65 Gross Margin 43.33% Net Profit Margin 5.87% Debt/Equity Ratio 68.4%
How did DIMP perform over the long term?
See historical performance and comparison Dividends
0.3% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/30 14:26 End of Day Share Price 2025/01/30 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Sartorius Stedim Biotech S.A. is covered by 31 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Stéphan Dubosq Arkeon Finance Charles Pitman-King Barclays Scott Bardo Berenberg
Show 28 more analysts 
